JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
JC virus (JCV) DNA in the cerebrospinal fluid (CSF) provides the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in patients whose clinical symptoms and magnetic resonance imaging findings are consistent with PML.The Laboratory of Molecular Medicine and Neuroscience (LMMN), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), made the confirmatory laboratory diagnosis in 35 multiple sclerosis (MS) patients treated with natalizumab. Thirteen patients had 3 or more CSF samples taken from weeks to months following PML diagnosis. Seven of the 13 patients demonstrated persistence of JCV DNA in the CSF even though all patients experienced immune reconstitution inflammatory syndrome (IRIS), 11 patients had plasma exchange, and 2 had immunoabsorption. Specific anti-JCV antibody was measured in plasma/sera samples from 25 of the 35 patients. Most of the samples showed moderate to high or rising antibody levels from the time of PML diagnosis. However, plasma from 1 patient at or near the time of PML diagnosis had a titer considered seronegative and 2 other plasma samples from patients had titers considered at baseline for seropositivity. In several PML cases, viral persistence and neurological deficits have continued for several years, indicating that once initiated, JCV infection may not entirely clear, even with IRIS.
Ryschkewitsch
Caroline F
CF
Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Jensen
Peter N
PN
Monaco
Maria Chiara
MC
Major
Eugene O
EO
D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D056915:DNA Copy Number Variations / Q000502:physiology; D004279:DNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism / Q000821:virology; D008137:Longitudinal Studies; D008297:Male; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000150:complications* / Q000821:virology; D000069442:Natalizumab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004279:DNA, Viral; D000069442:Natalizumab
J Med Virol. 2003 Sep;71(1):115-23
12858417
J Virol Methods. 2004 Nov;121(2):217-21
15381359
N Engl J Med. 2006 Mar 2;354(9):924-33
16510746
Nat Neurosci. 2005 Oct;8(10):1275
16189528
J Immunol. 2001 May 1;166(9):5346-55
11313370
J Gen Virol. 2006 Oct;87(Pt 10):2951-2960
16963754
N Engl J Med. 2005 Jul 28;353(4):375-81
15947078
Lancet Neurol. 2010 Apr;9(4):438-46
20298967
J Clin Microbiol. 2000 Jan;38(1):105-9
10618072
Annu Rev Med. 2010;61:35-47
19719397
N Engl J Med. 2009 Sep 10;361(11):1081-7
19741229
J Immunol. 2002 Jan 1;168(1):499-504
11751998